Illinois Municipal Retirement Fund Acquires 7,327 Shares of Illumina, Inc. $ILMN

Illinois Municipal Retirement Fund grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 115,293 shares of the life sciences company’s stock after buying an additional 7,327 shares during the quarter. Illinois Municipal Retirement Fund owned approximately 0.08% of Illumina worth $31,553,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Illumina in the 2nd quarter valued at about $3,374,423,000. WCM Investment Management LLC increased its position in shares of Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after acquiring an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA acquired a new stake in shares of Illumina in the second quarter valued at about $617,981,000. Ninety One UK Ltd raised its holdings in Illumina by 37,920.0% during the third quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock worth $372,198,000 after acquiring an additional 1,356,397 shares in the last quarter. Finally, Jupiter Topco LLC bought a new stake in Illumina during the second quarter worth about $358,652,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Down 2.7%

Illumina stock opened at $214.91 on Wednesday. The stock has a 50-day simple moving average of $249.27 and a 200 day simple moving average of $178.77. The stock has a market capitalization of $32.49 billion, a P/E ratio of 36.99, a PEG ratio of 3.00 and a beta of 1.46. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.26. The firm had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.34 earnings per share. Analysts expect that Illumina, Inc. will post 5.43 earnings per share for the current year.

Insider Activity at Illumina

In related news, Director Keith Meister sold 299,336 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the transaction, the director directly owned 1,409,851 shares of the company’s stock, valued at approximately $307,291,123.96. The trade was a 17.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 1,601,541 shares of company stock worth $354,755,291. Insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on ILMN shares. Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Guggenheim raised their price target on Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. JPMorgan Chase & Co. lowered their price target on Illumina from $320.00 to $300.00 and set an “overweight” rating on the stock in a research report on Friday, October 30th. Weiss Ratings upgraded Illumina from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday, November 2nd. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Illumina has an average rating of “Hold” and a consensus price target of $244.24.

About Illumina

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.